Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. (“CytoDyn” or the “Company”). On February 24, 2025, the Company announced increased survival rates in ...

In a rare move, the FDA has publicly accused US biotech CytoDyn of misrepresenting clinical trial results for leronlimab, an antibody being developed for COVID-19. It's not uncommon for drug ...

Nader Pourhassan, who led CytoDyn until in 2022, had drawn widespread attention — and scrutiny — for his relentless promotion ...

(RTTNews) - CytoDyn Inc. (CYDY.OB) has announced positive results from its preclinical studies in collaboration with SMC Laboratories, demonstrating the potential of leronlimab to reverse liver ...

VANCOUVER, Washington, Feb. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a ...

(OTCQB: CYDY) are on a tear as the biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced encouraging survival outcomes among ...

VANCOUVER, Washington, Feb. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a ...

CytoDyn (CYDY) announced survival outcomes among a group of patients with metastatic triple-negative breast cancer treated with leronlimab. Although mTNBC typically has a poor prognosis ...

Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. ("CytoDyn" or the "Company"). On February 24, 2025 ...

VANCOUVER, Washington, Feb. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential ...

(GLOBE NEWSWIRE) -- (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today ...